Novo Nordisk Toughens Long-Term Financial Targets As 2010 Sales Grew By 13%, Profits By 16%
This article was originally published in The Pink Sheet Daily
Executive Summary
Victoza and its modern insulins franchise drive 2010 revenues growth at Danish diabetes specialist Novo Nordisk.